Switch theme
Sign up to access all valuation multiples
SSY Group Ltd is engaged in the research, development, manufacturing, and selling of a wide range of pharmaceutical products, which include finished medicines of mainly intravenous infusion solutions and ampoule injections to hospitals and distributors, bulk pharmaceuticals, and medical materials. The company has two reportable segments, including intravenous infusion solutions and other medical materials. The company derives a vast majority of its revenue principally from the Intravenous infusion solution and others. Revenue generation is driven mostly by its sales of pharmaceutical products, followed by medical materials.
2005
6.1K+
LTM Revenue $742M
LTM EBITDA $200M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SSY Group has a last 12-month revenue (LTM) of $742M and a last 12-month EBITDA of $200M.
In the most recent fiscal year, SSY Group achieved revenue of $737M and an EBITDA of $238M.
SSY Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SSY Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $742M | XXX | $737M | XXX | XXX | XXX |
| Gross Profit | $380M | XXX | $371M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 50% | XXX | XXX | XXX |
| EBITDA | $200M | XXX | $238M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBIT | $171M | XXX | $172M | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 23% | XXX | XXX | XXX |
| Net Profit | $140M | XXX | $135M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $304M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SSY Group's stock price is HKD 3 (or $0).
SSY Group has current market cap of HKD 8.6B (or $1.1B), and EV of HKD 11.0B (or $1.4B).
See SSY Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.1B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SSY Group has market cap of $1.1B and EV of $1.4B.
SSY Group's trades at 1.9x EV/Revenue multiple, and 5.9x EV/EBITDA.
Equity research analysts estimate SSY Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SSY Group has a P/E ratio of 7.9x.
See valuation multiples for SSY Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.0x | XXX | 5.9x | XXX | XXX | XXX |
| EV/EBIT | 8.2x | XXX | 8.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 7.9x | XXX | 8.1x | XXX | XXX | XXX |
| EV/FCF | 21.1x | XXX | -222.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSSY Group's last 12 month revenue growth is 5%
SSY Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
SSY Group's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SSY Group's rule of X is 41% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SSY Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 32% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | -12% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 38% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 41% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 27% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SSY Group acquired XXX companies to date.
Last acquisition by SSY Group was XXXXXXXX, XXXXX XXXXX XXXXXX . SSY Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SSY Group founded? | SSY Group was founded in 2005. |
| Where is SSY Group headquartered? | SSY Group is headquartered in Hong Kong. |
| How many employees does SSY Group have? | As of today, SSY Group has 6.1K+ employees. |
| Who is the CEO of SSY Group? | SSY Group's CEO is Mr. Jiguang Qu. |
| Is SSY Group publicy listed? | Yes, SSY Group is a public company listed on HKG. |
| What is the stock symbol of SSY Group? | SSY Group trades under 02005 ticker. |
| When did SSY Group go public? | SSY Group went public in 2005. |
| Who are competitors of SSY Group? | Similar companies to SSY Group include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of SSY Group? | SSY Group's current market cap is $1.1B |
| What is the current revenue of SSY Group? | SSY Group's last 12 months revenue is $742M. |
| What is the current revenue growth of SSY Group? | SSY Group revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of SSY Group? | Current revenue multiple of SSY Group is 1.9x. |
| Is SSY Group profitable? | Yes, SSY Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SSY Group? | SSY Group's last 12 months EBITDA is $200M. |
| What is SSY Group's EBITDA margin? | SSY Group's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of SSY Group? | Current EBITDA multiple of SSY Group is 7.0x. |
| What is the current FCF of SSY Group? | SSY Group's last 12 months FCF is $66.4M. |
| What is SSY Group's FCF margin? | SSY Group's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of SSY Group? | Current FCF multiple of SSY Group is 21.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
